Testosterone Cypionate (Olympia) - CGMP Monitoring Issues (2022)
Class II: A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Class II recall indicates potential for temporary health effects.
This AI-generated summary is provided for general informational purposes only and is derived from publicly available recall notices. It supplements but does not replace official agency classifications or safety instructions.
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
Testosterone Cypionate 200 mg/mL (in Grapeseed Oil), Packaged in a) 10 mL Multi-Dose vial, NDC 73198-0054-10; b) 5 mL Multi-Dose vial, NDC 73198-0054-05, Rx Only, Olympia Pharmaceuticals 6700 Convoy Rd., Ste. 155, Orlando, FL 32835.
Brand
Olympia Compounding Pharmacy dba Olympia Pharmacy
Lot Codes / Batch Numbers
Lots: a) D48027 BUD: 4/27/2022, E47017 BUD: 5/17/2022, F42007 BUD: 6/7/2022, F42107 BUD: 6/7/2022, F42207 BUD: 6/7/2022, F48009 BUD: 6/9/2022, F48109 BUD: 6/9/2022, H47003 BUD: 8/3/2022, b) F24024 BUD: 6/24/2022
Products Sold
Lots: a) D48027 BUD: 4/27/2022,E47017 BUD: 5/17/2022, F42007 BUD: 6/7/2022, F42107 BUD: 6/7/2022, F42207 BUD: 6/7/2022, F48009 BUD: 6/9/2022, F48109 BUD: 6/9/2022, H47003 BUD: 8/3/2022; b) F24024 BUD: 6/24/2022
Olympia Compounding Pharmacy dba Olympia Pharmacy is recalling Testosterone Cypionate 200 mg/mL (in Grapeseed Oil), Packaged in a) 10 mL Multi-Dose vial, NDC 73198 due to CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly invest. This is a Class I recall, indicating a high risk of serious health consequences. Based on FDA drug enforcement report.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated
Recommended Action
Per FDA guidance
Consumers should stop using the product and contact the recalling firm, their healthcare provider, or return it to the place of purchase.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 7, 2026